Related Experiment Videos
Inhibition of spontaneous mouse mammary tumour development by antineoplaston A10
Abstract:
Antineoplaston A10, a human urinary product of minimal toxicity and demonstrable antineoplastic activity, was examined as a modulator of spontaneous mammary tumour development in C3H+ mice. These animals normally express the viral response with appearance of tumours in greater than 95% of the mice by 9-10 months of age. Inclusion of A10 as a 1% dietary supplement from the age of 3 months dramatically increased the disease-free interval. At 10-11 months of age, none of the animals had developed tumours, and the incidence reached 95% only at 21 months of age. In spite of this effect, the survival interval following tumour detection could not be prolonged by treatment with A10. Male C3H+ mice, normally fully protected against spontaneous mammary tumour by their testicular androgens, can be made susceptible to such tumorigenesis by castration. The age at which castration is performed influences the age of onset of the disease: castration at one month leads to initial appearance at 5 months of age; castration at 2 months to appearance at 7-8 months. When such animals are maintained on A10-containing diets following castration, the onset of tumour appearance is delayed until 7 months and 10 months for the 1- and 2-month castrated animals respectively. The results indicate a clear inhibitory action of A10 on MMTV-induced spontaneous mammary tumour occurrence in a manner similar to the protective effect of androgens.
Insights
Antineoplaston A10 significantly delays mammary tumor development in mice by inhibiting MMTV. While it extends the disease-free period, it does not improve survival after tumor detection.
Area of Science:
- Oncology
- Biochemistry
- Animal Models
Background:
- Spontaneous mammary tumors in C3H+ mice are typically induced by MMTV, with >95% incidence by 9-10 months.
- Antineoplaston A10 is a urinary product with low toxicity and known antineoplastic effects.
- Male C3H+ mice are generally protected from mammary tumors by androgens, but castration induces susceptibility.
Purpose of the Study:
- To investigate Antineoplaston A10's efficacy in modulating spontaneous mammary tumor development in C3H+ mice.
- To assess the impact of Antineoplaston A10 on the disease-free interval and survival post-tumor detection.
- To evaluate Antineoplaston A10's effect on mammary tumorigenesis in castrated male mice.
Main Methods:
- C3H+ mice received a 1% Antineoplaston A10 dietary supplement from 3 months of age.
- Mammary tumor development, disease-free interval, and survival were monitored.
- Castrated male mice were treated with Antineoplaston A10 post-surgery to assess tumor onset delay.
Main Results:
- Dietary Antineoplaston A10 dramatically increased the disease-free interval; no tumors were observed at 10-11 months, with 95% incidence delayed to 21 months.
- Antineoplaston A10 did not prolong survival after tumor detection.
- In castrated mice, Antineoplaston A10 delayed tumor onset, with delays of 2 and 3 months observed in mice castrated at 1 and 2 months, respectively.
Conclusions:
- Antineoplaston A10 demonstrates significant inhibitory activity against MMTV-induced spontaneous mammary tumors in mice.
- The compound's action mimics the protective effect of androgens in preventing mammary tumorigenesis.
- Further research is warranted to explore Antineoplaston A10's therapeutic potential in oncology.